FIC

China Medical System （867.HK）2023 Annual Results: Despite of the Temporary Financial Performance Pressure Fresh Catalysts Emerged from Successive Innovation Breakthroughs

Retrieved on: 
Thursday, March 28, 2024
Sclerotherapy, RMB, Conditional sentence, NDA, IND, Creativity, Small RNA, Marketing, Gastroenterology, Central nervous system, FIC, City, BIC, CMS, NRDL, Injection, Dermatology, CDMO, Commercialization, Tablet, Pharmacy, Methotrexate, Hospital, Acquisition, Gonadotropin-releasing hormone, RCT, VBP, Rheumatoid arthritis, Growth, Varicose veins, Ecosystem, Blue, Government, Ophthalmology

SHENZHEN, CHINA, March 27, 2024 (GLOBE NEWSWIRE) -- On March 27, 2024, China Medical System (“CMS” or the “Company”) released its 2023 annual results.

Key Points: 
  • SHENZHEN, CHINA, March 27, 2024 (GLOBE NEWSWIRE) -- On March 27, 2024, China Medical System (“CMS” or the “Company”) released its 2023 annual results.
  • Based on above, CMS has successfully entered into its “New Period” of innovation and internationalization development.
  • 4 innovative drugs have started large-scale clinical application, unveiling CMS’s first year of commercialization era of innovative drugs.
  • Under its compliant and efficient commercialization system, the Company's innovative products and exclusive drugs will grow steadily.

FIC AR HUD: Innovative Technology Elevating the Driving Experience to New Heights

Retrieved on: 
Thursday, February 22, 2024
Metaverse, FIC, FOV, Algorithm, LBS, Multimedia, ADAS, HUD, Reality, VID, Safety, IVI, Voice recognition, Environment

FIC AR HUD is uniquely designed based on the LBS technology, which brings up high contrast, high brightness, and low power consumption.

Key Points: 
  • FIC AR HUD is uniquely designed based on the LBS technology, which brings up high contrast, high brightness, and low power consumption.
  • Providing the high-resolution AR image under FOV angle from 6~42 degrees and the VID of 3~50 meters are the leading spotting lights of FIC AR HUD.
  • FIC Laser AR HUD is on the road to advanced AR HUD and plans ahead to become the portal of the In-Vehicle Metaverse.
  • The development of AR HUD technology opens up further possibilities for the future driving experience.

Specialty Food Association Opens Submissions for Evolved 2024 sofi Awards

Retrieved on: 
Thursday, February 8, 2024
Gala, Hearing, FIC, Specialty Food Association, Social media, Award, Rutgers University, Creativity, Senior, Gold, Gold Award, Kefir

NEW YORK, Feb. 8, 2024 /PRNewswire/ -- The Specialty Food Association (SFA) has opened submissions to the sofi™ Awards, a celebration of culinary excellence and creativity and food's most coveted prize.

Key Points: 
  • NEW YORK, Feb. 8, 2024 /PRNewswire/ -- The Specialty Food Association (SFA) has opened submissions to the sofi™ Awards, a celebration of culinary excellence and creativity and food's most coveted prize.
  • All sofi winners receive promotion at the Fancy Food Shows and via SFA media, publicity and social media support, and branding tools and resources.
  • Attendees of the Summer Fancy Food Show will have the chance to celebrate the sofi Award winners at the Gala on June 24, 2024.
  • The Summer Fancy Food Show is open only to qualified members of the specialty food trade, industry affiliates, and media.

EPA Taps Fordham to Manage $50M Environmental Justice Grant Program

Retrieved on: 
Wednesday, December 20, 2023
Biophysical environment, Community of practice, School, Fordham University, Faculty, Learning, Multimedia, University, Student, Religion, Research, Science, Postgraduate education, Education, FIC, Climate, Practice, Asthma, Climate change, EPA, Teaching, Social work, STEM, Nursing

NEW YORK, Dec. 20, 2023 /PRNewswire/ -- Fordham University has been awarded a $50 million grant focused on environmental justice, issued through a competitive grant process by the U.S. Environmental Protection Agency (EPA). Fordham will serve as a grantmaker to community-based groups in New York, New Jersey, Puerto Rico, and the U.S. Virgin Islands and will also fund the environmental research of its own faculty.

Key Points: 
  • NEW YORK, Dec. 20, 2023 /PRNewswire/ -- Fordham University has been awarded a $50 million grant focused on environmental justice, issued through a competitive grant process by the U.S. Environmental Protection Agency (EPA) .
  • Fordham is one of just 11 institutions nationwide selected to manage $550 million in federal funds earmarked for the program.
  • "Fordham University stands for impact on the world and finding solutions to the most urgent problems," said President Tania Tetlow.
  • Serving as the EPA Region 2 grantmaker for the project, called the 2023 Environmental Justice Thriving Communities Grantmaking Program, Fordham will allocate the remaining $40 million in subgrants ranging from $75,000 to $350,000 to foster various environmental justice initiatives.

Mirum Pharmaceuticals Presents New Data at The Liver Meeting®

Retrieved on: 
Monday, November 13, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Sleep, Hepatology, MDR3, Self-harm, Safety, Hepatocellular carcinoma, Bilirubin, Cholestasis, AASLD, Liver, Disease, Risk, Cholestatic pruritus, Hematology, Quality of life (healthcare), MYO5B, PFIC, Patient, Publication, Pregnancy, Nature, TJP2, Ascending cholangitis, GI, Hippeastrum mirum, Liver support system, Volixibat, ICP, IBAT, Progressive familial intrahepatic cholestasis, FIC, Augmented fifth, Growth, Doctor of Philosophy, Quality of life, AND, Itch, Medication, MCID, HIV disease progression rates, SBA, Chloride, Pharmaceutical industry, Nursing, Medical imaging, Dietary supplement, Boston, BSEP

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced new data from its LIVMARLI and volixibat programs presented at The Liver Meeting®, the American Association for the Study of Liver Diseases (AASLD) annual meeting in Boston, Massachusetts.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced new data from its LIVMARLI and volixibat programs presented at The Liver Meeting®, the American Association for the Study of Liver Diseases (AASLD) annual meeting in Boston, Massachusetts.
  • “PFIC is a chronic, debilitating cholestatic liver disease characterized by elevated bile acids and pruritus so severe that patients can be listed for liver transplant even in the absence of disease progression.
  • These data suggest overall improved liver health with maralixibat treatment in patients with PFIC that can be maintained long-term.
  • No clinically meaningful changes in liver enzyme levels or hematology parameters were observed after volixibat treatment.

Riding the tide, realize the future: The BD paths for Chinese Biotech

Retrieved on: 
Wednesday, November 15, 2023
Chronic kidney disease, DDR, Observation, Research, Policy, Return, Spacecraft, Biology, ROI, Kidney disease, Disease, ADC, Climate, Risk, Learning, Technology policy, Patient, Multinational corporation, Science, Partner, PD-1, Return on investment, Partnership, BIC, CMO, FIC, Metabolic disorder, Growth, BioCity Nottingham, Business, Face, Health, Philosophy, Pharmaceutical industry, Typesetting, Fine chemical, Sales, Risk management, Guardian

Form both angles, he shared his views on Chinese biotech transformation and the key points and prospects of BD collaboration between Chinese biotech and MNCs.

Key Points: 
  • Form both angles, he shared his views on Chinese biotech transformation and the key points and prospects of BD collaboration between Chinese biotech and MNCs.
  • The clear recognition of the success of this approach is evident by the recent partnerships between multiple multinational pharma and relatively small Chinese biotech companies.
  • Q: What are MNCs prioritizing for potential collaborations, and what are the key points to be taken for Chinese biotech?
  • We have now begun to reach out to MNCs to socialize our clinical stage programs to explore potential partnership paths.

Best’s Special Report: Best’s Impairment Rate and Rating Transition Study — 1977 to 2022

Retrieved on: 
Friday, November 3, 2023
Other Professional Services, Professional Services, Insurance, Delta, ICR, AM Best, News, FIC, AM, Rehabilitation, Cyclone, FSR, Risk, Zeta, Credit, Impairment rating, ALL, FICS

There were two insurers added to gross impairments in 2022, down from 10 carriers identified in the previous year.

Key Points: 
  • There were two insurers added to gross impairments in 2022, down from 10 carriers identified in the previous year.
  • The Best’s Special Report, titled, “Best’s Impairment Rate and Rating Transition Study — 1977 to 2022,” marks AM Best’s 20th study and is aimed at estimating the risk of impairment of U.S. insurers.
  • The analysis covers 45 one-year periods from Dec. 31, 1977, to Dec. 31, 2022, and includes U.S. insurers that had at least one Best’s Financial Strength Rating (FSR) or one corresponding Long-Term Issuer Credit Rating (ICR) during the study period.
  • None were rated by AM Best at the time of impairment, with 11 companies never rated by AM Best.

Citi Successfully Settles First Trades on HKEX Synapse Platform

Retrieved on: 
Monday, October 9, 2023
Banking, Professional Services, Business, Citigroup, HKEX, Stock Connect, FIC, T+1, HK, Trust, Connect, Public sector banks in India, API, Acceleration, Cryptocurrency, China Asset Management, Synapse

Citi Securities Services announced the successful settlement of trades for China Asset Management (Hong Kong) [ChinaAMC (HK)] on Hong Kong Exchanges and Clearing Limited (HKEX) Synapse platform, which went live for trades settlement today.

Key Points: 
  • Citi Securities Services announced the successful settlement of trades for China Asset Management (Hong Kong) [ChinaAMC (HK)] on Hong Kong Exchanges and Clearing Limited (HKEX) Synapse platform, which went live for trades settlement today.
  • This was among the first trades executed and settled on the newly launched Synapse platform.
  • HKEX Head of Emerging Business and FIC, Glenda So, said: “We warmly welcome Citi as one of the inaugural participants to HKEX Synapse.
  • Citi is the first participant to fully integrate its custody platform with Synapse, enabling seamless execution of trades from Day 1.

BNP Paribas Appoints Scott Carter as Global Head of Investor Coverage

Retrieved on: 
Monday, September 18, 2023
Banking, Professional Services, Finance, AQR Capital, Public sector banks in India, Multimedia, Carbon, Deutsche Bank, Scott, BNP Paribas, Financial intermediary, Financial sponsor, Partner, Pension, FIC, BNP, Growth, Bank, Asset, Security (finance), Insurance

BNP Paribas, Europe’s leading bank, announces the appointment of Scott Carter as Global Head of Investor Coverage.

Key Points: 
  • BNP Paribas, Europe’s leading bank, announces the appointment of Scott Carter as Global Head of Investor Coverage.
  • View the full release here: https://www.businesswire.com/news/home/20230918164709/en/
    Scott Carter, newly appointed Global Head of Investor Coverage at BNP Paribas (Photo: Business Wire)
    The Investors’ sector (consisting of Asset Managers, Hedge Funds, and Pension Funds) is one of the most dynamic institutional client segments, with significant opportunities for growth across the bank’s Global Markets and Securities Services activities.
  • BNP Paribas is well-positioned to provide comprehensive investor solutions that meet the evolving needs of institutional investors worldwide.
  • We welcome Scott to our management team and look forward to continuing working closely with all our investor clients together with our senior bankers in the US, EMEA, and APAC.”
    Scott recently joined BNP Paribas in September 2023 as Global Head of Investor Coverage.

SinoMab's IND Application of SM17 has once again Received Approval from NAMP

Retrieved on: 
Tuesday, September 12, 2023
Asthma, T helper cell, Therapy, Prevalence, Infection, Quality of life, Atopic dermatitis, Research, Innate lymphoid cell, Investigational New Drug, Patient, FIC, ILC2, National Medical Products Administration, Cytokine, Mortality, AD, IND, NMPA, Autoimmunity, Skin, Conditional sentence, Pharmaceutical industry

Current approved therapies for AD, including biologics, can significantly improve eczema area and severity index and patient's quality of life.

Key Points: 
  • Current approved therapies for AD, including biologics, can significantly improve eczema area and severity index and patient's quality of life.
  • The Company actively promoted the indication research of SM17, laying a foundation for subsequent proof of concept and commercialization.
  • The IND application of SM17 for AD has been approved by the NMPA, which fully reflects the recognition of the differentiated advantages of SM17 in the field of AD and has a bright future.
  • Currently, SM17 has obtained IND approvals from the NMPA for the treatment of asthma and AD, while our Phase I study for SM17 conducted in the US is near completion.